| 摘要 |
The pharmaceutical compositions for the treatment of lipid metabolism disorders, especially arteriosclerosis and multiple sclerosis, contain as active substance at least one straight-chain unsaturated aldehyde with 12 to 24 C atoms, preferably those with an even number of C atoms, in particular 6-n-dodecanaldehyde, 8-n-hexadecenaldehyde, 6,12-n-octadecadienaldehyde and/or 2-hydroxy-8,16-n-tetracosadienaldehyde plus and/or 8-n-hexadecenoic acid, 2-hydroxy-8,16-n-tetracosadienoic acid, where appropriate together with conventional vehicles and/or aids. The active substances can also be in the form of acetates, ethers, salts or esters.
|
